The mechanism of Annexin A1 to modulate TRPV1 and nociception in dorsal root ganglion neurons
Cell & Bioscience volume 11, Article number: 167 (2021)
Annexin A1 (ANXA1) exerts anti-nociceptive effect through ANXA1 receptor formyl peptide receptor 2 (FPR2/ALX (receptor for lipoxin A4), FPR2) at the dorsal root ganglia (DRG) level. However, the mechanisms remain elucidated. By using radiant heat, hot/cold plate, tail flick, von Frey, and Randall-Selitto tests to detect nociception in intact and chemical (capsaicin, menthol, mustard oil, formalin or CFA) injected AnxA1 conditional knockout (AnxA1−/−) mice, applying calcium imaging and patch clamp recordings in cultured DRG neurons to measure neuronal excitability, conducting immunofluorescence and western blotting to detect the protein levels of TRPV1, FPR2 and its downstream molecules, and performing double immunofluorescence and co-immunoprecipitation to investigate the interaction between Calmodulin (CaM) and TRPV1; we aim to uncover the molecular and cellular mechanisms of ANXA1’s role in antinociception.
AnxA1−/− mice exhibited significant sensitivity to noxious heat (mean ± SD, 6.2 ± 1.0 s vs. 9.9 ± 1.6 s in Hargreaves test; 13.6 ± 1.5 s vs. 19.0 ± 1.9 s in hot plate test; n = 8; P < 0.001), capsaicin (101.0 ± 15.3 vs. 76.2 ± 10.9; n = 8; P < 0.01), formalin (early phase: 169.5 ± 32.8 s vs. 76.0 ± 21.9 s; n = 8; P < 0.05; late phase: 444.6 ± 40.1 s vs. 320.4 ± 33.6 s; n = 8; P < 0.01) and CFA (3.5 ± 0.8 s vs. 5.9 ± 1.4 s; n = 8; P < 0.01). In addition, we found significantly increased capsaicin induced Ca2+ response, TRPV1 currents and neuronal firing in AnxA1 deficient DRG neurons. Furthermore, ANXA1 mimic peptide Ac2-26 robustly increased intracellular Ca2+, inhibited TRPV1 current, activated PLCβ and promoted CaM-TRPV1 interaction. And these effects of Ac2-26 could be attenuated by FPR2 antagonist Boc2.
Selective deletion of AnxA1 in DRG neurons enhances TRPV1 sensitivity and deteriorates noxious heat or capsaicin induced nociception, while ANXA1 mimic peptide Ac2-26 desensitizes TRPV1 via FPR2 and the downstream PLCβ-Ca2+-CaM signal. This study may provide possible target for developing new analgesic drugs in inflammatory pain.
Though currently available analgesics including opioids and cannabinoids have therapeutic benefits, long-term use causes unintended toxicity and serious side effects . Nonsteroidal medications are potentially harmful to the heart, liver, and kidney when used as adjunctive analgesics . Therefore, it is necessary to develop novel analgesics with low toxicity and side effects.
Annexin A1 (ANXA1) is a calcium and phospholipid binding protein that belongs to the annexin superfamily. Studies show ANXA1 effectively alleviates nociception elicited by a variety of nociceptive stimuli [3, 4]. Our previous study in rats found that intrathecal injecting ANXA1 mimic peptide Ac2-26 into the lumbar region effectively decreased hyperalgesia in complete Freund's adjuvant (CFA) induced inflammatory pain . Furthermore, intrathecal injection of BMS-986235, an agonist of ANXA1 receptor formyl peptide receptor 2 (FPR2) mimicked the anti-nociceptive effects of Ac2-26, which can be reverted by the FPR2 blocker Boc2 [6,7,8]. Both ANXA1 and FPR2 were found to be strongly expressed in dorsal root ganglion (DRG) neurons and spinal dorsal horn, which are linked to the development of nociception . Recently, Christabel Fung et al. reported that the spinal cord contained high levels of FPR2 protein . These studies indicate that ANXA1 may elicit anti-nociceptive effect through FPR2 both peripherally and centrally.
TRPV1 is considered to be a detector and integrator of nociception, and modulation of TRPV1 is implicated in hypersensitivity, and shown to contribute to several conditions of pain . Although numerous studies have demonstrated the role of TRPV1 in pain, whether ANXA1-FPR2 regulates the sensitivity of TRPV1 to participate in nociception is unclear.
In this study, by using conditional knockout mice, combining a variety of pain behavioral measurements, Ca2+ imaging, whole cell patch recording and co-immunoprecipitation, we investigated whether deletion of ANXA1 in DRG affects nociception and TRPV1 function through FPR2 signal in DRG neurons. We aim to elucidate the mechanism of ANXA1 to modulate TRPV1-mediated nociception in mice.
AnxA1 −/− mice are more sensitive to noxious heat stimuli and capsaicin induced nociception
We previously demonstrated that ANXA1 has anti-nociceptive effects through FPR2 at the DRG level . Therefore, we asked whether selective deletion of ANXA1 in DRG affects nociception. We generated AnxA1 conditional knockout (AnxA1−/−) mice (Fig. 1a) and explored the consequences of AnxA1−/− in thermal, mechanical, chemical and inflammatory nociception. The control littermates (Con.), and homozygous (AnxA1−/−) knockout mice were validated by genotyping (Fig. 1b). AnxA1−/− mice showed normal hair, body shape and body weight as compared with control littermates (Fig. 1 c). Immunofluorescence staining confirmed that ANXA1 was completely abolished in the DRG (Fig. 1d).
Pain behavioral results showed that the thermal latency of AnxA1−/− mice was significantly decreased in both Hargreaves test (6.2 ± 1.0 s) and hot plate test (13.6 ± 1.5 s) as compared with control littermates (9.9 ± 1.6 and 19.0 ± 9.9 s, respectively) (P < 0.001; Fig. 1e, f). However, no difference was found in cold plate assay (Fig. 1g) test, von Frey test (Fig. 1h), or Randall-Selitto test (Fig. 1i) between AnxA1−/− and control mice. Among chemical stimuli, only intraplantar injection of capsaicin (25 µg), but not menthol (40 µg) or mustard oil (5%), induced exacerbated licking/biting behavior in AnxA1−/− mice (101.0 ± 15.3 times) compared with control (76.2 ± 10.9 times) (P < 0.01; Fig. 1j). These results suggest that AnxA1−/− mice exhibit increased responsiveness to noxious thermal stimuli and capsaicin-induced nociception.
In the formalin test, the licking/biting time was significantly increased both in the early phase (0–15 min, 169.5 ± 32.7 s vs. 76.0 ± 21.9 s) and later phase (15–60 min, 444.6 ± 40.1 s vs. 320.4 ± 33.6 s) after injection of formalin into one hindpaw of AnxA1−/− mice (P < 0.05 in 0–15 min; P < 0.01 in 15–60 min; Fig. 1k). Our previous study showed that the pain response peaked one week after the CFA injection. Therefore, in this study, the Hargreaves test and von Frey test were performed on day 7 after unilateral intraplantar injection of CFA. We observed that AnxA1−/− mice displayed a significant reduction in thermal latency (Veh: 6.2 ± 1.1 s, CFA: 3.6 ± 0.8 s) compared to control littermates (Veh: 9.9 ± 1.7 s, CFA: 5.9 ± 1.4 s) (P < 0.01; Fig. 1l). However, the threshold of von Frey test has no obvious difference between AnxA1−/− and control mice in either Veh or CFA group (P = 0.83; P = 0.85; Fig. 1m). These results suggest that AnxA1−/− mice exhibit increased spontaneous pain and inflammatory thermal hyperalgesia.
AnxA1 deficiency does not affect the expression of FPR2 and nociceptive receptors in DRG neurons
Since nociceptive responses induced by noxious heat and capsaicin were enhanced in AnxA1−/− mice, and TRPV1 has no binding site of ANXA1 , we speculate that AnxA1 deficiency in DRG might affect the expression of FPR2 or TRPV1. We detected the co-localizations of TRPV1 with FPR2 in mice L4-6 DRGs neurons by using double immunofluorescent staining. Both FPR2 and ANXA1 were found to be dispersed and colocalized with TRPV1 in the DRG neurons of control mice (Fig. 2a, Additional file 1a). AnxA1 deletion has no effect on FPR2 and TRVP1 expression in DRG neurons (Fig. 2a). The average number of FPR2 positive (FPR2+) neurons is 49.0 ± 10.4 and 50.7 ± 9.9 in control and AnxA1−/− mice, respectively. And the average number of TRPV1 positive (TRPV1+) neurons is 128.4 ± 11.4 and 122.8 ± 11.1 in control littermates and AnxA1−/− mice, respectively (P = 0.45; P = 0.78; Additional file 1b). In addition, the average percentage of FPR2 and TRPV1 double positive (FPR2+/TRPV1+) neurons are highly close in the two genotypes (24.36 and 23.23%, respectively) (Fig. 2b).
Next, we further analyzed the protein levels of ANXA1, FPR2 and TRPV1 in L4-6 DRGs by western blotting. Consistent with the staining results, ANXA1 protein was absent in the AnxA1−/− mice (Additional file 1c), but abundantly expressed in the DRGs of the control littermates without significantly affecting the expression of FPR2 (P = 0.45; Fig. 2c, d). Furthermore, the protein levels of TRPV1, TRPA1 and TRPM8 in the DRGs also have no difference between AnxA1−/− and control mice (P = 0.32; P = 0.82; P = 0.85; Fig. 2c, e–h). In addition, FPR2 showed similar co-labeling pattern with TRPA1, and TRPM8 (the overlapping rates are 12.3, and 16.6% respectively) (Additional file 2). Thus, AnxA1 deletion has no effect on FPR2 expression or FPR2 co-localization with TRPV1 in DRG neurons.
AnxA1 deficiency increases capsaicin induced Ca2+ responses in DRG neurons
Since AnxA1 deletion has no effect on TRPV1 expression, we suppose the increased nociceptive response after AnxA1 deletion is due to increased sensitivity of DRG neurons to nociceptive stimuli. To verify this hypothesis, we detected capsaicin mediated Ca2+ response by using ratiometric calcium imaging in cultured neurons derived from the L4-6 DRGs of AnxA1−/− mice and control littermates. Our results showed that 1 µM capsaicin induced a slight increase of Ca2+ response during 30 s applications, which was recovered toward baseline following 50 s. Whereas 10 µM capsaicin elicited a robust increase of Ca2+ response in cultured DRG neurons of AnxA1−/− mice compared to cultures of control mice (20.4 ± 9.2 vs. 12.9 ± 4.1%, n = 9, P < 0.001; Fig. 3a–c). However, we did not observe any difference of Ca2+ response between the two genotype groups when DRG neurons treated with mustard oil (10, 100 µM) (P = 0.99; P = 0.64; Fig. 3d, e), or menthol (10, 100 µM) (P = 0.78; P = 0.78; Fig. 3f, g) either at lower or higher concentration. Taken together, the results indicate that ANXA1 specifically modulates TRPV1 responses, but not TRPA1 or TRPM8.
AnxA1 deficiency enhances capsaicin induced TRPV1 sensitivity in DRG neurons.
To further verify AnxA1 deletion enhances the sensitivity of DRG neurons, we investigated whether AnxA1−/− could affect the intrinsic firing properties of DRG neurons by using whole-cell current-clamp recording. AnxA1−/− cultures fired more repetitive action potentials than the control neurons after injection of 100 pA or 200 pA current (100 pA: 11.8 ± 6.6 vs. 5.9 ± 3.4 Hz; 200 pA: 24.3 ± 11.48 vs. 12.5 ± 5.9 Hz; n = 10, P < 0.0001; Fig. 4a–c). However, both the resting membrane potential (59.7 ± 1.9 and 60.2 ± 2.1 mV for control and AnxA1−/− neurons, respectively, n = 10 neurons/group) and the amplitude of action potentials were not significantly changed (61.6 ± 2.3 and 59.6 ± 2.6 mV for control and AnxA1−/− neurons, respectively, n = 10 neurons/group) (P = 0.26; Fig. 4a–c).
To determine whether the increased neuronal activity caused by AnxA1 deletion is attributable to the increased TRPV1 sensitivity, we then recorded the DRG neurons under voltage clamp. Bath application of capsaicin (10 μM) elicited typical inward TRPV1 currents in both control and AnxA1−/− cultures (Fig. 4d). However, the AnxA1−/− group displayed larger TRPV1 current trace and significantly higher capsaicin gated current density than the control group (23.0 ± 3.7 vs. 15.0 ± 2.8 pA/pF; n = 8, P < 0.001; Fig. 4d, e), although the activation and deactivation time constants were not changed between the two genotypes (P = 0.81; P = 0.55; Fig. 4f). We also applied mustard oil (100 μM) and menthol (100 μM) to the cultures and then recorded the evoked currents. Neither TRPA1 nor TRPM8 current traces were obviously altered in the DRG cultures of the two genotypes (Fig. 4g, j). Similarly, no significant difference was observed in mustard oil and menthol gated current density between the two groups (P = 0.61; P = 0.94; Fig. 4h, k). In addition, neither activation nor deactivation time constants of TRPA1, or TRPM8 were affected in AnxA1−/− DRG neurons as compared with control group (P = 0.79; P = 0.87; Fig. 4i; P = 0.43; P = 0.59; Fig. 4l). Together with the calcium imaging results, these findings consistently demonstrate that AnxA1 deletion increases DRG neuronal excitability, and sensitizes responses to TRPV1.
ANXA1 mimic peptide Ac2-26 increases intracellular Ca2+ and activates PLCβ via FPR2
Given that the AnxA1 deficiency could sensitize TRPV1 in DRG neurons, we hypothesize that ANXA1 may reduce TRPV1 sensitization. Next, we applied exogenous ANXA1 mimetic peptide Ac2-26 (3.3 μM) or the scrambled peptide (Scramble, 3.3 μM) as the control into the cultured AnxA1−/− DRG neurons. The ratiometric calcium imaging was used again to detect whether Ac2-26 influences the intracellular calcium concentration ([Ca2+]i). The results showed that Ac2-26 induced a remarkable increase of [Ca2+]i in DRG cultures as compared with scramble control (200.3 ± 23.9 vs. 28.9 ± 12.7; n = 9, P < 0.001). However, Ac2-26 co-treatment with FPR2 antagonist Boc2 (10 μM) significantly inhibited the increase of [Ca2+]i in cultured DRG neurons (85.3 ± 16.0 vs. 200.3 ± 23.9; n = 8, P < 0.01; Fig. 5a–c).
To elucidate whether the increase of [Ca2+]i is mediated by the activation of FPR2 downstream signal phospholipase C beta (PLCβ), we detected the active form of PLCβ (phosphorylated PLCβ, pPLCβ), and the total PLCβ after applying Ac2-26 or Boc2 with Ac2-26. The results showed that Ac2-26 alone robustly increased the protein level of pPLCβ, while co-application of Boc2 with Ac2-26 apparently inhibited the increase of pPLCβ (P < 0.001; Fig. 5d, e). Neither Ac2-26 nor Boc2 with Ac2-26 altered the protein level of total PLCβ (Fig. 5d). Since the specific inhibitor for PLCβ is not commercially available at this stage, we did not perform further experiment by using inhibitors to validate this signaling pathway. Together, these results indicate that the increase of intracellular Ca2+ induced by Ac2-26 is mainly mediated by FPR2 and its downstream PLCβ.
Ac2-26 promotes CaM-TRPV1 interaction and desensitizes TRPV1 via FPR2
CaM is activated once it binds to Ca2+ and functions as part of a calcium signal transduction pathway by influencing its interactions with target proteins. It is known that the intracellular domain (amino acids 767–801 of COOH-terminal region) of TRPV1 binds CaM in a Ca2+-dependent manner . Therefore, we deduce that Ac2-26-FPR2 induced increase in intracellular Ca2+ promotes CaM-TRPV1 binding in DRG neurons. To prove this, we used double immunofluorescence staining to detect the interaction of TRPV1 and CaM in cultured DRG cells. The staining results showed that Ac2-26 obviously increased the co-localization of TRPV1 and CaM (intensities of TRPV1+/CaM+ cells) in DRG neurons as compared with scramble control (56.6 ± 9.8 vs. 30.8 ± 7.7, n = 10, P < 0.0001; Fig. 6a, b). However, co-application of Boc2 with Ac2-26 reversed the increasing of TRPV1+/CaM+ intensities in DRG cells (40.8 ± 7.5 vs. 56.6 ± 9.8; n = 10, P < 0.001; Fig. 6a, b). To further confirm these results, we performed co-immunoprecipitation experiments and found that Ac2-26 promoted the interaction between TRPV1 and CaM. And the enhanced interaction between the two proteins was markedly attenuated by co-treatment of Boc2 with Ac2-26 (Fig. 6c, d).
The Ca2+-CaM/TRPV1 interaction was found to reduce TRPV1 channel open probability15 and desensitize TRPV1 in a calcium dependent manner . Therefore, we speculate that Ac2-26-FPR2 signal induced CaM-TRPV1 interaction may lead to the desensitization of TRPV1, ultimately decreasing nociceptive transmission at the DRG level. Subsequently, we used capsaicin to activate TRPV1 in AnxA1−/− DRG neurons. The patch clamp recording results showed that capsaicin (Cap., 100 nM) elicited an obvious inward current in AnxA1−/− DRG neurons. However, exposure to Ac2-26 (3.3 μM) produced an apparent decrease in the capsaicin activated current (0.5 ± 0.1 vs. 1.0 ± 0.0; n = 8, P < 0.0001; Fig. 6e, f). After co-application of Boc2 (10 μM) with Ac2-26 (3.3 μM), the effect of Ac2-26 on TRPV1 current was markedly reversed (0.8 ± 0.1 vs. 0.5 ± 0.1; n = 8, P < 0.0001; Fig. 6e, f). In addition, we found a similar desensitized effect of Ac2-26 on TRPV1 current via FPR2 in wild type DRG neurons (Ac2-26 vs. Scramble: 0.5 ± 0.1 vs. 1.0 ± 0.0; Boc2 + Ac2-26 vs. Ac2-26: 0.9 ± 0.2 vs. 0.5 ± 0.1; n = 10, P < 0.0001; Additional file 3a, b).
The desensitization of TRPV1 caused by Ac2-26-FPR2 signal was further confirmed in vivo on AnxA1−/− mice with inflammatory pain. In formalin mice model, intrathecal injection of Ac2-26 (1 mg/kg, 10 μl, 1 h before the formalin injection) decreased the licking and biting time by 45–50% in the first peak of nociception (62.6 ± 12.1 vs. 109.0 ± 17.1; n = 8, P < 0.01; Additional file 4a) and 30% in the second peak compared to scramble control (213.0 ± 20.6 vs. 317.0 ± 36.4; n = 8, P < 0.001; Additional file 4a). However, the anti-nociceptive effect was reversed by co-application of the FPR2 antagonist Boc2 (10 mg/kg, 10 μl) with Ac2-26 (0–15 min: 91.9 ± 17.1 vs. 62.6 ± 12.1; n = 8, P = 0.02; 15–60 min: 280.6 ± 29.3 vs. 213.0 ± 20.6; n = 8, P < 0.01; Additional file 4a). Similarly, In CFA induced inflammatory pain, intrathecal Ac2-26 application (1 mg/kg, 10 μL, 12 h and 1 h before the formalin injection) significantly increased the thermal pain latency by 30–40% (9.6 ± 1.8 vs. 6.7 ± 1.1; n = 10, P < 0.01; Additional file 4b), which was abolished by co-administration of Boc2 with Ac2-26 (7.3 ± 0.8 vs. 9.6 ± 1.8; n = 10, P < 0.01; Additional file 4b). Overall, these results suggest that Ac2-26 promotes CaM-TRPV1 interaction and desensitizes TRPV1 via FPR2/ALX, and finally exerts anti-nociceptive effects in inflammatory pain at the DRG level.
In this study, we show that genetic deletion of ANXA1 selectively promotes thermal and capsaicin induced hyperalgesia by enhancing TRPV1 function in dorsal root ganglion neurons. Furthermore, ANXA1 mimic peptide Ac2-26 desensitizes TRPV1 through FPR2-PLCβ-Ca2+-CaM signaling at the DRG level. Our study reveals the mechanism by which ANXA1 exerts antinociceptive effect in inflammatory pain.
ANXA1 is a glucocorticoid mediated anti-inflammatory protein that is encoded by the AnxA1 gene  and involved in innate and adaptive immunity , cancer diseases , and inflammation  Early studies found ANXA1 peptidomimetics have analgesic effects in inflammatory pain both peripherally and centrally [16, 17]. Our previous study in rats also have shown the analgesic effects of Ac2-26 in CFA induced inflammatory pain at the DRG level . In addition, ANXA1 inhibits remifentanil-induced hyperalgesia via regulating spinal CXCL12/CXCR4 in rats . Here we found that deletion of ANXA1 enhances noxious sensations to capsaicin, thermal stimuli and inflammation, which is consistent with Ayoub’s discovery that global AnxA1 knockout mice are more vulnerable to inflammatory visceral pain induced by intraperitoneal acetic acid injection than wild-type mice .
Based on the results that AnxA1 deficiency selectively increases heat or capsaicin, but not cold, mechanical, mustard oil or menthol induced nociception, we assume that deletion of AnxA1 may specifically affect the functions of TRPV1 instead of TRPA1 or TRPM8. Indeed, AnxA1 knockout had no effect on TRPV1 expression, but increased the sensitivity of the TRPV1 ion channel, as shown by calcium imaging and whole cell patch clamp recordings. Despite the fact that ANXA1 and TRPV1 co-localize in DRG neuronal cells, there is no clear evidence demonstrating their direct interaction.
Our results show 10 μM capsaicin-induced robust Ca2+ response in AnxA1−/− DRG neurons as compared with control. In this case, capsaicin directly activates TRPV1, which causes basal calcium influx. Once the AnxA1 is deleted, TRPV1 becomes more sensitized under capsaicin stimulation, and this non-selective cation channel opens more frequently, which leads to plenty of extracellular Ca2+ influx and results in a greater Ca2+ response. We also found 3.3 μM Ac2-26 induced dramatic increase of Ca2+ signal when compared with scramble peptide in AnxA1−/− DRG neurons. In this situation, Ac2-26 directly activates FPR2 and the downstream PLCβ, which increases the second messenger IP3 in the cytoplasm. It is known that IP3 interacts with IP3 receptor and facilitates calcium release from endoplasmic reticulum stores, thus causing a large increase in intracellular Ca2+ concentration and producing a significant increase in Ca2+ response. This result is consistent with a study in polymorphonuclear cells showing that the activated heterotrimeric Gi/o-protein of FPR2 by ANXA1 dissociates into α and βγ subunits, activating downstream PLCβ and phosphoinositide 3-kinase (PI3K). Activated PLCβ converts phosphatidylinositol 3, 4, 5-triphosphate (PIP3) into diacylglycerol (DAG) and inositol-1, 4, 5-triphosphate (IP3), which facilitates calcium release from endoplasmic reticulum stores [19,20,21,22]. Overall, these studies suggest that ANXA1-FPR2 signaling is conserved and plays a pivotal role in anti-inflammation and pro-resolution of inflammation, corroborating our previous findings that ANXA1 inhibits CFA induced inflammatory pain in rats via FPR2 in DRGs .
The most significant finding of this study is that ANXA1-FPR2 signaling increases intracellular calcium and activates CaM, which interacts with TRPV1, decreases TRPV1 sensitivity and relieves nociception. Although intracellular Ca2+ is necessary for neuronal excitation and synaptic transmission, excessive intracellular Ca2+ can decrease cellular excitability . For example, higher Ca2+ may prevent sodium from moving through voltage-gated sodium channels, resulting in reduced depolarization and action potential generation . Furthermore, the release of calcium from internal stores can reduce neuron excitability  suggesting that drugs that cause calcium release from stores may also affect neuronal excitability. In Xenopus oocytes and HEK 293 cells, Ca2+ and CaM form a complex of Ca2+/CaM that binds to the intracellular NH2-terminal domain of TRPV1 and inhibits gating to reduce channel open probability . As a result, the significantly elevated Ca2+ in DRG sensory neurons that express TRPV1 can cause channel closure and desensitization to noxious sensory stimuli. In addition, the structure of TRPV1’s cytosolic ankyrin repeat domain (ARD) has been identified as a CaM binding site, which is essential in channel sensitivity regulation . Thus, desensitization of TRPV1 by ANXA1/FPR2 via downstream Ca2+/CaM/TRPV1 may represent a feedback mechanism that not only protects the cell from excitotoxicity of excessive Ca2+, but also contributes to the analgesic effects of Ac2-26.
In conclusion, we showed that selective deletion of AnxA1 in DRG neurons enhanced noxious heat or capsaicin induced nociception, increased capsaicin-mediated Ca2+ response, and enlarged capsaicin-induced TRPV1 current in mice DRG neurons. ANXA1 mimic peptide Ac2-26 can increase intracellular Ca2+, activate CaM, promote the interaction between CaM and TRPV1, desensitize TRPV1 through FPR2, and finally reduce nociceptive transmission and exerts analgesic effects (Additional file 5).
Materials and methods
Generation of AnxA1 conditional knockout (AnxA1 −/−) mice.
The exon 6 of the AnxA1 targeting construct was flanked by loxP sites followed by a FRT-flanked NEO cassette. The targeting vector was inserted into r1 embryonic stem cells (129/Sv, ThermoFisher Scientific) with electroporation. Neomycin-resistant cells were selected with geneticin (G418 Sulfate, ThermoFisher Scientific, Cat# 10,131,035). The confirmed positive clones were injected to blastocysts of C57BL/6 mice, which produced substantial chimeric mice. To generate heterozygous mice with one loxP-flanked allele (AnxA1loxP/+), the chimeric mice were bred with C57BL/6 mice. Next, the NEO cassette was deleted by crossing AnxA1loxP/+ mice with FLP deleter mice (B6.129S4-Gt(ROSA)26Sortm1(FLP1)Dym/RainJ, Jackson Laboratory, stock 009,086). To specifically delete AnxA1 gene in DRG, NEO cassette deficient AnxA1loxP/+ mice were crossed with Avilcre mice to produce Avilcre; AnxA1loxP/+ mice, which were then crossed with AnxA1loxP/+ mice to generate ANXA1 conditional knockout (AnxA1−/−) mice (Avilcre; AnxA1loxP/loxP). The littermates (Avilcre-AnxA1+/+) with the same age and sex were used as control. All mice were genotyped two weeks after birth, using reverse-transcription PCR with specific primers (forward, 5’- GGTGTGAATGAAGACTTGGCTGA-3’ and reverse, 5’- GTTTCATCCAGGATGGCTTGGCA -3’).
All the animals were fed on a standard chow pellet diet with tap water ad libitum in the standard conditions (22 ± 2℃ temperature, 40–60% humidity) with a 12 h light/dark cycle at the Specific-Pathogen-Free (SPF) facility. All animal procedures were conducted with the approval of the Animal Ethics Committee of Huazhong University of Science and Technology and with the guidelines of Editorial by Drummond JC and Guide for the Care and Use of Laboratory Animals [27, 28] Sample sizes of 8 to 10 mice per group were used in each animal experiments.
The ANXA1 mimetic peptide and the scrambled control peptide ANXA1 2–26 (Ac2-26, acetyl-AMVSEFLKQAWFIENEEQEYVQTVK) and the scramble peptide (acetyl-YESQFKAVWVE-INTQQMLKFEAEEV) were generated from GenicBio Limited (Shanghai, China) by using solid-phase stepwise synthesis. The FPR2 antagonist N-t-Boc-Phe-Leu-Phe-Leu-Phe (Boc2) were purchased from Calbiochem (San Diego, CA, USA). Other materials were obtained from Sigma-Aldrich (Saint Louis, US). Ac2-26 and Boc2 were applied into the bath solution of cultured DRG neurons in a volume of 10 μL. When co-administered Boc2 with Ac2-26, we applied the first single-drug injection combined with the equivalent vehicle volume of the second drug. Drugs were freshly dissolved in saline each test day. Boc2 stock solutions were prepared by dissolving the compounds in dimethylsulphoxide (DMSO); aliquots of this solution were used for subsequent dilution in saline (DMSO: saline 1:3, v/v). We chose these doses based upon our preliminary experiments.
Thermal and mechanical pain behavior measurements
Thermal and mechanical was measured according to our previous protocol [5, 29] and the operations of the algometer follows the procedures of the manual guide (Ugo basil). All the behavioral experiments were conducted starting at 9:00 AM every day. Before the experiments, animals were acclimatized for 30 min in a transparent Plexiglas box in the room for pain measurements. Each mouse was tested three times, with intervals of 10 min (Please see supplementary materials for the detailed information).
Hot plate test
The hot plate used in this study was a Series 8 Model 39 (IITC Life Sciences, US). The temperature in the hot plate was set to 50℃ with a cut-off time of 45 s and typically left for at least 30 min in order to prevent the plate temperature from fluctuating beyond ± 0.1 °C during the experiment. Mice were placed on the hot plate as gently as possible with the experimenter using a foot switch to activate the internal timer with accuracy up to a hundredth of a second. We used the paw licking as the readout of pain response. Use the time of onset of pain response as the pain latency.
The Hargreaves test instrument used in this study was a BW-Plantar 390 (IITC Life Sciences, US). A radiative heat source was placed beneath the animal and pointed at the plantar surface of the hindpaw. The time between the onset of the thermal radiation stimulus and the appearance of paw withdrawal was recorded as the hindpaw withdrawal thermal latency.
Von Frey test
Classical top-down methods  were used to detect the mechanical threshold of the mice hindpaw withdrawal to the von Frey filaments (Product #58,011; Set of 20 monofilaments: Stoelting Co., Wood Dale, IL, USA) stimuli. Mice under test were placed on the metal grid with pores (2 mm × 2 mm) and separated with polyethylene chamber (8 cm × 8 cm × 15 cm). After waiting for the mice to adapt to the chamber, using von Frey filaments with different force intensity to poke the hindpaw skin area between the third and four toes. Stimulus intensity typically starts at 0.4 g. If the filament bent more than 90 degrees and the mouse still do not lift their feet, it will be considered unresponsive. Then, adjacent filaments with a higher stimulus intensity should be given. If there is a response, adjacent filaments with a lower stimulus intensity should be replaced. Each stimulation interval must be longer than 10 s until a filament is found that causes a 50% lift-off response. The maximum stimulation force was 4.0 g. Record the stimulation intensity that could cause 50%-foot lifting response in the tested mice as the mechanical threshold of the hindpaw withdrawal.
Cold plate test
Before the cold plate test, set plate (Series 8, PE34, IITC Life Sciences, US) temperature to match that of the test room (25 ± 2℃), clean test plate surface and place mice into the chamber on the plate to acclimate for 30 min. The metal plate was cooled down to 4 °C and the time of the onset of pain behavior such as lifting, shaking, licking or jumping of the paws is defined as the response latency. As soon as the behavioral response is seen, quickly remove the mouse from the test surface to avoid unnecessary suffering or tissue damage. After finishing the test, remove mouse into a separate cage from untested mice. Clean any urine or feces from the plate surface, and return the test plate temperature to that of the room and clean surface in preparation for next mouse.
Using a Paw Pressure Test Apparatus (Part# 2500, IITC Life Sciences, US) to perform the Randall-Selitto test. Before testing, mouse was placed into the restrainer for habituation until its breathing is normal and mouse is not agitated. Then the mouse’s tail was placed onto the pedestal of the Randall-Selitto apparatus. A point on the tail approximately one quarter of the way down from the base of the tail was chosen so that the animal could withdraw the tail easily. Pressure was applied to the foot pedal to increase the weight exerted onto the tail. The foot pedal was released and the blunt cone was lifted at the first sign of struggling, vocalization, or withdrawal of the tail. The number reached on the scale was recorded and multiplied by the weights to obtain the final force exerted on the tail.
Chemical nociception measurements
A week before the test, gently handling the mice for several times to reduce animals’ stress response. On the testing day, mice were placed into the transparent Perspex box for habituation until its exploratory behavior has ceased. Then took the mice from the box for injection. Insert the 0.3 ml disposable insulin syringe needle into the center of the hindpaw at a shallow angle and subcutaneously inject the indicated dose of different chemicals (capsaicin (500 µg/ml, Sigma-Aldrich), 5% mustard oil (Sigma-Aldrich), menthol (0.8 mg/ml, Fisher Scientific), or 2% formalin (Fisher Scientific) in a total volume of 50 μl dissolved in saline). The mice should not bleed during or after injection. Finally, the mice were placed back into the Perspex box and use the stopwatch to record the time spent conducting nocifensive behaviors (licking or biting) for the desired amount of time (Menthol, mustard oil, capsaicin for 5 min and formalin for 60 min, respectively).
Complete Freund’s adjuvant (CFA) and nociception tests
Mice were anesthetized with 1% isoflurane and injected with 20 μl of Vehicle (saline, buffered with 20 mM HEPES, pH 7.4) or complete Freund’s adjuvant (CFA, 0.5 mg/ml heat-killed M. tuberculosis; Sigma, St. Louis, MO) in the plantar surface of the hind paw to induce chronic inflammation. Based on our previous work,5 the Hargreaves test and von Frey test described above are used to assess thermal hyperalgesia and mechanical allodynia on day 7 after CFA injection. Please see supplementary materials for the detail information.
Acute isolation and culture of DRG neurons
Both AnxA1−/− mice and control littermates were euthanized by asphyxiation method (CO2) followed by decapitation. L4, L5 and L6 DRGs were quickly removed, carefully dissected and placed in ice-cold Ringer's solution (130 mM NaCl, 3 mM KCl, 2 mM CaCl2, 2 mM MgSO4, 1.25 mM KH2PO4, 26.2 mM NaHCO3, and 10 mM dextrose and filled with 95% O2 and 5% CO2, pH = 7.4, osmolality of 290–310 mOsm). They were digested with calcium-free standard Ringer's solution containing 1.0% collagenase type II (collagenase, 265 U/mg; Worthington Biochemical Corp., Lakewood, NJ) for 30 min at 37℃ and then washed in Ringer's solution for 10 min. DRG cells were dissociated by pipetting with a polished Pasteur dropper and transferred to polynaphthylamine-coated coverslips containing Medium 199 (Sigma Chemicals Co., St. Louis, MO) with 10% fetal bovine serum and 1,000 U/ml penicillin and streptomycin. DRG cells were cultured in a 37 °C incubator (containing 5% CO2).
Calcium imaging was performed 48 h after plating the cells. Intracellular [Ca2+]i labeling was performed using the Ca2+-sensitive fluorescent dye fura-2. Indicators were applied by adding 5 μM fura-2 acetoxymethyl ester to DRGs neurons for 45 min at 37° C. Fura-2 acetoxymethyl ester dissolve in HEPES-buffered Hanks' saline solution (HHSS, pH 7.45, in mM): 20 HEPES, 137 NaCl; 1.3 CaCl2, 0.4 MgSO4, 0.5 MgCl2, 5.4 KCl, 0.4 KH2PO4, 0.3 Na2HPO4, 3.0 NaHCO3 and 5.6 glucose) with 0.5% bovine serum albumin (BSA). Subsequently, the coverslips with attached cells were placed in the detection chamber of the inverted microscope (Olympus IX70 microscope, Olympus Optical, Tokyo, Japan). Before the experiment, HHSS was continuously filled in the chamber at a rate of 1.0 to 1.5 ml/min for 10 min. Ca2+ signal was detected via a 40 × objective of the microscope (UApo/340, numerical aperture = 1.35). Fura-2 digital images were acquired by Optoscan monochromator (Cairn Research LTD, Faversham, Kent, UK) with fast conversion at 340 nm (8 nm bandwidth) and 380 nm. Emitted light at 517 (30) nm (Roper, Tucson, AZ) was detected using a step-cooled charge-coupled camera. Images were analyzed using Metafluor image software (Molecular Devices, Sunnyvale CA). The fluorescence change was converted to [Ca2+]i after calculation by the formula [Ca2+]i = Kdβ (R-Rmin)/(Rmax-R). R represents the fluorescence ratio of 340/380 nm. Kd represents the dissociation constant of 140 nM fura-2, and β represents the ratio of the 380 nm fluorescence emission light in the absence of Ca2+ to 380 nm fluorescence emission light in the presence of Ca2+. Rmin, Rmax, and β were determined by Ca2+-free buffer enomycin (1 mM EGTA) and saturated Ca2+ buffer (5 mM Ca2+) in the cell bath, and the values of Rmin, Rmax, and β were 0.237, 4.10, and 6.52, respectively. The composition of the internal solution containing EGTA was as follows (in mM): CsCl 150, MgATP 5.0, Li4GTP 0.1, EGTA 10, CaCl2 3.0 (free Ca2+ concentration ∼100 nm) as well as HEPES 10 (pH 7.2 adjusted with CsOH).
Whole-cell patch-clamp recordings
TRPV1 currents were recorded using an Axopatch 200B ultra-low-noise patch-clamp amplifier (Axon Instruments, USA). DRG neurons were placed in an open recording bath filled with Ringer's solution (mM: 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose, pH 7.4, 21 °C). Glass electrodes (recording electrodes, 1.65 ± 0.05 μm outer diameter) were pulled with an electrode puller and filled with an internal solution of electrodes (mM: 140 KCl, 5 MgCl2, 4 Na2ATP, 0.3 Na3GTP, 2.5 CaCl2, 5 EGTA, and 10 HEPES, pH 7.2) with an electrode resistance of 2–4 MΩ before recording. In whole-cell mode, the current and voltage of neurons were maintained at 0 and less than − 45 mV for 5 min, respectively. Capsaicin (10 μM), Mustard oil (10 mM), Menthol (100 μM), ATP (10 μM), Ac2-26 (10 μM), Boc2 (100 μM) (the antagonist of FPR2), and saline (vehicle control) were applied to adjacent recording cells through a gravity-driven drug-loading perfusion system. All testing was performed at approximately 22 °C. The clamp voltage (Vh) was set to − 60 mV for all experiments, and capsaicin evoked currents were recorded in voltage clamp mode. Divide the whole-cell current by the cell capacitance to calculate the current density. Capsaicin evoked whole-cell currents were filtered and the signal sampling frequency was 1 kHz. Membrane potentials were expressed as absolute values (millivolts, mV), and TRPV1 currents were expressed as absolute values (nanoamperes, nA) or multiples of changes compared with basal values. To detect neuronal excitability, the rheobase was measured in current-clamp mode by input step currents (100 pA for 500 ms). The rheobase was reflected by the change in the basal value of the stimulus current intensity (normalized to the basal value 1) and expressed as a percentage.
Double immunofluorescent staining
Mice were deeply anesthetized with 5% isoflurane and transcardially perfused with normal saline, followed by cold (4 °C) 4% paraformaldehyde (0.01 M PBS, pH 7.4). The L4-6 DRGs were removed, postfixed in 4% paraformaldehyde overnight, and then treated with 30% sucrose (in 0.1 M PB, pH 7.4) till tissues sink to the bottom of the container. Cryosections (10 μm) were cut, mounted on slides, and stored at − 20 °C. For immunofluorescent staining, DRG sections were treated with 10% TritonX-100 for 30 min. Nonspecific binding sites were blocked with 5% fetal bovine serum for 30 min after washing with PBS for 10 min, followed by incubation with rabbit polyclonal antibody against TRPV1 (1:500, Cat#ab6166, Abcam), rabbit polyclonal antibody against TRPA1 (1:2000, Cat#OST00061W, Invitrogen), rabbit polyclonal antibody against TRPM8 (1:1000, Cat#OSR00077W, Invitrogen), mouse monoclonal antibody against FPR2 (1:1000, Cat#H00002358-M02, Abnova), and mouse monoclonal antibody against Calmodulin (1:1000, Cat#05-173, Sigma-Aldrich), overnight at 4 °C. Then, the sections were washed with PBS for three times and 5 min each, and incubated (room temperature, 1 h) with FITC-labeled donkey anti- rabbit antibody (1:2000; Cell Signaling) and Cy3-labeled donkey anti-mouse antibody (1:2000; Cell Signaling). After cover the sections with fluorescent bleach-proof mounting medium and cover slides, fluorescent signal was detected using a Zeiss confocal fluorescence microscope (ZEISS510 META, Germany). Image J software (Bethesda, MD, USA) was used to analyze the acquired images. For immunofluorescent staining with cultured DRG cells, the cells were first rinsed with pre-warmed (37 °C) PBS, and then fixed with cold (4 °C) 4% paraformaldehyde for 20 min and then washed three times with PBS for 5 min each. The rest of the procedures were the same as for DRG sections. All immunoreactive positive profiles in a section or cultured dish were outlined, creating an artificial overlay. Counting of double-labelled cells was conducted on 6 confocal images randomly taken from two view fields from each section or cultured dish with Image J software.
Cultured cells were homogenized with cold lysate containing 0.1% SDS, 50 mM Tris–HCl, 150 mM NaCl, 1% NP-40, 2 mM EDTA, 0.5% sodium deoxycholate, 1% Triton X-100, 1% deoxycholate, and 1 mM phenylmethylsulfonyl fluoride (PMSF), followed by rapid sonication and centrifugation at 12,000 g for 30 min at 4℃ to collect the lysate. Protein concentration was measured with the Bradford assay (Bio-Rad, Hercules, CA). The lysate was incubated with non-specific IgG (2 mg, Sigma-Aldrich, Cat#12-371), polyclonal rabbit anti-TRPV1 (2 mg, Alomone Labs, Cat #ACC-030), or monoclonal mouse anti-Calmodulin (2 mg, Sigma-Aldrich, Cat#05-173) overnight at 4 ℃. Then, added Protein G-Sepharose (2 mg/ml, Millipore, Cat#P3296) for 3 h at 4 ℃. The pellet was washed 4 times with lysis buffer, denatured with SDS sample buffer and proteins were separated with 12% SDS-PAGE gel. Next, the proteins were transferred to nitrocellulose membranes by wet transfer using Bio-Rad's protein electrophoresis transfer tank overnight at 4 ℃, and then the membranes were blocked with 5% non-fat milk for 1 h at room temperature. After three washes, they were incubated with rabbit polyclonal antibody against TRPV1 (1:1000, Cat#ab6166, Abcam) and mouse monoclonal antibody against Calmodulin (1:1000, Cat#05-173, Sigma-Aldrich) for 1 h at room temperature. Membranes were washed three times for 10 min with buffer of TBST and incubated with horseradish peroxidase-labeled goat anti-rabbit (1:2000, Cat#7074, Cell Signaling) and horse anti-mouse (1:2000, Cat#7076, Cell Signaling) secondary antibody for 1 h at room temperature. Lanes labeled "input" were loaded with 10% immunoprecipitated protein lysate. Finally, the band signals were detected with an enhanced chemiluminescence detection kit (Amersham Biosciences, Arlington, IL). The intensity of the band signal at the position corresponding to CaM and TRPV1 or CaM and FPR2 reflects the degree of interaction between the two proteins.
Mice were euthanized by rapid cervical dislocation. The L4-6 DRGs were quickly removed and homogenized in ice-cold lysis buffer (pH 7.5, 50 mM Tris–HCl) including 0.1% cholic acid, 150 mM NaCl, 0.1% Nonidet P40, 2 mg/ml leupeptin, 2 mM EDTA, 1 mg/ml pepstatin and 2 mM phenylmethylsulfonyl fluoride. The homogenates were centrifuged at 15,000 g for 10 min at 4 °C to yield the total protein extract in the supernatant. The protein concentrations were measured according to the previously described methods.5 Each lysate (30 μg) was separated on sodium dodecyl sulfate polyacrylamide gel electrophoresis gels and transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad) using a semidry electrotransfer system (Amersham Biosciences). Then, incubating the membranes with primary antibodies (rabbit polyclonal anti-ANXA1 (sc‐11387, 1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse monoclonal antibody against FPR2 (1:1000, Cat#H00002358-M02, Abnova), polyclonal rabbit anti-TRPV1 (1:1000, Cat#ACC-030, Alomone Labs), rabbit polyclonal antibody against TRPA1 (1:2000, Cat#OST00061W, Invitrogen), rabbit polyclonal antibody against TRPM8 (1:1000, Cat#OSR00077W, Invitrogen), mouse monoclonal antibody against Calmodulin (1:1000, Cat#05-173, Sigma-Aldrich), mouse monoclonal anti-PLCβ (1:500, Cat#05-164, Sigma-Aldrich) and rabbit polyclonal anti-pPLCβ (1:1000, #2481, Cell Signaling)) at 4 °C overnight. Next, the PVDF membranes were washed and incubated with corresponding secondary antibodies. To control the loading differences in total protein amounts, antibody to protein β-actin (1:5000, Cat#ABT264, Sigma-Aldrich) was used. The signal and intensity of the band on the PVDF membrane were detected using Odyssey system (Li-Cor Bioscience, Lincoln, NB, USA).
All variance values in the study were represented as mean ± SD. Statistical analyses were conducted by the software GraphPad prism 8.0 (San Diego, CA). Two-way ANOVA with repeated measures was used to compare the data of bodyweight gain between the two genotypes. Pain behavioral results were analyzed by unpaired t-test. Western blotting data were analyzed by unpaired t-test (for two groups) or one-way analysis of variance (ANOVA) (for more than two groups) with the Student–Newman–Keuls (SNK) tests. Percentage of calcium responses were analyzed by unpaired t-test. Action potential frequencies were analyzed by two-way ANOVA repeated measures with Tukey’s multiple comparisons test. Current density and Tau were analyzed by unpaired t-test. [Ca2+] concentration, peak current and number of positive cells among three groups were analyzed by one-way ANOVA with the Student–Newman–Keuls (SNK) tests. P denotes the significance (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001) and refers to the respective control or indicated group.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Formyl peptide receptor 2/receptor for lipoxin A4
Dorsal root ganglia
Transient receptor potential vanilloid 1
Complete Freund's adjuvant
- AnxA1 − / − :
AnxA1 Conditional knockout
- [Ca2 +]i:
Intracellular calcium concentration
Phospholipase C beta
Phosphatidylinositol 3, 4, 5-triphosphate
Inositol-1, 4, 5-triphosphate
Ankyrin repeat domain
Cumenal M, Selvy M, Kerckhove N, Bertin C, Morez M, Courteix C, Busserolles J, Balayssac D. The safety of medications used to treat peripheral neuropathic pain, part 2 (opioids, cannabinoids and other drugs): review of double-blind, placebo-controlled, randomized clinical trials. Expert Opin Drug Saf. 2021;20:51–8.
Weingarten TN, Taenzer AH, Elkassabany NM, Wendling LL, Nin O, Kent ML. Safety in acute pain medicine-pharmacologic considerations and the impact of systems-based gaps. Pain Med. 2018;19:2296–315.
Chen L, Lv F, Pei L. Annexin 1: a glucocorticoid-inducible protein that modulates inflammatory pain. Eur J Pain. 2014;18:338–47.
Ayoub SS, Yazid S, Flower RJ. Increased susceptibility of annexin-A1 null mice to nociceptive pain is indicative of a spinal antinociceptive action of annexin-A1. Br J Pharmacol. 2008;154:1135–42.
Pei L, Zhang J, Zhao F, Su T, Wei H, Tian J, Li M, Shi J. Annexin 1 exerts anti-nociceptive effects after peripheral inflammatory pain through formyl-peptide-receptor-like 1 in rat dorsal root ganglion. Br J Anaesth. 2011;107:948–58.
Luo Z, Wang H, Fang S, Li L, Li X, Shi J, Zhu M, Tan Z, Lu Z. Annexin-1 mimetic peptide Ac2-26 suppresses inflammatory mediators in LPS-induced astrocytes and ameliorates pain hypersensitivity in a rat model of inflammatory pain. Cell Mol Neurobiol. 2020;40:569–85.
Gastardelo TS, Damazo AS, Dalli J, Flower RJ, Perretti M, Oliani SM. Functional and ultrastructural analysis of annexin A1 and its receptor in extravasating neutrophils during acute inflammation. Am J Pathol. 2009;174:177–83.
Bena S, Brancaleone V, Wang JM, Perretti M, Flower RJ. Annexin A1 interaction with the FPR2/ALX receptor: identification of distinct domains and downstream associated signaling. J Biol Chem. 2012;287:24690–7.
Ho C, Ismail N, Koh J, Gunaseelan S, Low Y, Ng Y, Chua J, Ong W. Localisation of formyl-peptide receptor 2 in the rat central nervous system and its role in axonal and dendritic outgrowth. Neurochem Res. 2018;43:1587–98.
Abbas MA. Modulation of TRPV1 channel function by natural products in the treatment of pain. Chem Biol Interact. 2020;330:109178.
Numazaki M, Tominaga T, Takeuchi K, Murayama N, Toyooka H, Tominaga M. Structural determinant of TRPV1 desensitization interacts with calmodulin. Proc Natl Acad Sci U S A. 2003;100:8002–6.
Rosenbaum T, Gordon-Shaag A, Munari M, Gordon SE. Ca2+/calmodulin modulates TRPV1 activation by capsaicin. J Gen Physiol. 2004;123:53–62.
Wallner BP, Mattaliano RJ, Hession C. Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. Nature. 1986;320:77–81.
Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids–new mechanisms for old drugs. N Engl J Med. 2005;353:1711–23.
Zhang Z, Huang L, Zhao W, Rigas B. Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo. Cancer Res. 2010;70:2379–88.
Peers SH, Smillie F, Elderfield AJ, Flower RJ. Glucocorticoid-and non-glucocorticoid induction of lipocortins (annexins) 1 and 2 in rat peritoneal leucocytes in vivo. Br J Pharmacol. 1993;108:66–72.
Ferreira SH, Cunha FQ, Lorenzetti BB, Michelin MA, Perretti M, Flower RJ, Poole S. Role of lipocortin-1 in the anti-hyperalgesic actions of dexamethasone. Br J Pharmacol. 1997;121:883–8.
Pieretti S, Giannuario AD, Felice MD, Perretti M, Cirino G. Stimulus-dependent specificity for annexin 1 inhibition of the inflammatory nociceptive response: the involvement of the receptor for formylated peptides. Pain. 2004;109:52–63.
Hidaka S, Kanai Y, Takehana S, Syoji Y, Kubota Y, Uotsu N, Yui K, Shimazu Y, Takeda M. Systemic administration of alpha-lipoic acid suppresses excitability of nociceptive wide-dynamic range neurons in rat spinal trigeminal nucleus caudalis. Neurosci Res. 2019;144:14–20.
Gierschik P, Sidiropoulos D, Jakobs KH. Two distinct Gi-proteins mediate formyl peptide receptor signal transduction in human leukemia (HL-60) cells. J Biol Chem. 1989;264:21470–3.
Wenzel-Seifert K, Arthur JM, Liu HY, Seifert R. Quantitative analysis of formyl peptide receptor coupling to Giα1, Giα2, and Giα3. J Biol Chem. 1999;274:33259–66.
Senchenkova EY, Ansari J, Becker F, Vital SA, Al-Yafeai Z, Sparkenbaugh EM, Pawlinski R, Stokes KY, Carroll JL, Dragoi AM, Qin C, Ritchie RH, Sun H, Cuellar-Saenz HH, Rubinstein MR, Han Y, Wayne Orr A, Perretti M, Granger DN, Gavins F. Novel role for the AnxA1-Fpr2/ALX signaling axis as a key regulator of platelet function to promote resolution of inflammation. Circulation. 2019;140:319–35.
Segal M. Calcium stores regulate excitability in cultured rat hippocampal neurons. J Neurophysiol. 2018;120:2694–705.
Armstrong CM, Cota G. Calcium block of Na+ channels and its effect on closing rate. Proc Natl Acad Sci U S A. 1999;96:4154–7.
Koplas PA, Rosenberg RL, Oxford GS. The role of calcium in the desensitization of capsaicin responses in rat dorsal root ganglion neurons. J Neurosci. 1997;17:3525–37.
Lishko PV, Procko E, Jin X, Phelps CB, Gaudet R. The ankyrin repeats of TRPV1 bind multiple ligands and modulate channel sensitivity. Neuron. 2007;54:905–18.
Drummond JC, Todd MM, Saidman LJ. Use of neuromuscular blocking drugs in scientific investigations involving animal subjects: the benefit of the doubt goes to the animal. Anesthesiology. 1996;85:697–9.
National Research Council (US) Committee for the update of the guide for the care and use of laboratory animals: guide for the care and use of laboratory animals, 8th edn. Washington (DC): National Academies Press (US); 2011.
Pei L, Lin C, Dai J, Yin G. Facial pain induces the alteration of transient receptor potential vanilloid receptor 1 expression in rat trigeminal ganglion. Neurosci Bull. 2007;23:92–100.
Deuis JR, Dvorakova LS, Vetter I. Methods used to evaluate pain behaviors in rodents. Front Mol Neurosci. 2017;10:284.
We would like to thank Prof. Vijay Samineni from Washington University School of Medicine for the English language editing. Additional file 5 Summary graph created with Biorender.com.
This work was supported by National Natural Science Foundation of China (81870932, 81571078, 81200863).
Ethics approval and consent to participate
All animal procedures were conducted with the approval of the Animal Ethics Committee of Huazhong University of Science and Technology and with the guidelines of Editorial by Drummond JC and Guide for the Care and Use of Laboratory Animals.
Consent for publication
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
: ANXA1 is completely deleted in the DRG sensory neurons of AnxA1-/- mice. (a) Representative images of double immunofluorescence staining on cryosections of mouse L4-6 DRGs colabeled for ANXA1 and TRPV1 in control mice (Con., upper panel) and AnxA1-/- littermates (AnxA1-/-, lower panel). Scale bar, 100 μm. (b) Statistical bar graph shows the number of TRPV1 positive and FPR2 positive cells in DRG between the AnxA1-/- mice and control littermates. (c) Representative western blots band images and the quantification of the indicated proteins (d) ANXA1 (AnxA1-/- versus control group, ****P < 0.00001, Student’s t test. n=6 in WT group, n=6 in AnxA1-/- group).
: FPR2 co-expressed with TRPA1 and TRPM8 in DRG neurons of AnxA1-/- mice. (a and c) Representative images of double immunofluorescence staining on cryosections of mouse DRG co-labeled for FPR2 and TRPA1 in AnxA1-/- mice (c). (b and d) Venn diagram corresponding to the images in left panels showing the percentages of FPR2 positive and TRPA1 positive (a) or FPR2 positive and TRPM8 positive (c) neurons in DRG sections from ANXA1-/- mice as indicated. Scale bar, 100 μm.
: Ac2-26 inhibits TRPV1 currents via FPR2 in DRG neurons of wild type mice. (a) Whole-cell current responses to applications of capsaicin (Cap.; 100 nM) + scramble, capsaicin + Ac2-26 (3.3 μM) and capsaicin + Boc2 (10 μM) + Ac2-26 (3.3 μM), respectively. (b) Statistic bar graph shows the fold change peak current in (a), scramble control was normalized to 1 for comparison. (Ac2-26 versus scramble group, ****P<0.0001; Ac2-26 versus Boc2+Ac2-26 group, ****P<0.0001, one-way ANOVA, post hoc Tukey’s multiple comparisons test, n=10 in each group). All data are represented as mean±SD.
: Ac2-26 alleviates inflammatory pain via FPR2 in AnxA1-/- mice. (a) Quantitative analysis of the licking or biting duration over 60 min after injection of 1% formalin into the hindpaw of AnxA1-/- mice (0-15 min: Ac2-26 versus scramble group, n=8, **P < 0.01; Boc2+Ac2-26 versus Ac2-26 group, n=8 *P < 0.05; 15-60 min: Ac2-26 versus scramble group, n=8, ***P < 0.001; Boc2+Ac2-26 versus Ac2-26 group, n=8 **P < 0.01; Two-way ANOVA, Sidak’s multiple comparisons test, n=8 in each group). (b) Quantitative analysis of the withdrawal latency to radiant heat in Hargreaves test (Ac2-26 versus scramble group, n=10, **P < 0.01; Boc2+Ac2-26 versus Ac2-26 group, n=10, **P < 0.01; One-way ANOVA, post hoc Tukey’s multiple comparisons test) in AnxA1-/- mice treated with after unilateral injection of CFA.
: Summary graph. (Left) Genetic deletion of AnxA1 (AnxA1-/-) increases capsaicin mediated Ca2+ response and TRPV1 current in DRG neurons, and selectively enhances noxious heat or capsaicin induced pain sensation. (Right) ANXA1 mimic peptide Ac2-26 binds with FPR2, activates FPR2 coupled Gi/o signaling pathway, increases intracellular Ca2+, which binds to calmodulin (CaM) and enhances CaM-TRPV1 interaction, thus desensitizes TRPV1, finally decreases the nociceptive transmission and exerts analgesic effects.
About this article
Cite this article
Zhang, Y., Ma, S., Ke, X. et al. The mechanism of Annexin A1 to modulate TRPV1 and nociception in dorsal root ganglion neurons. Cell Biosci 11, 167 (2021). https://doi.org/10.1186/s13578-021-00679-1